Articles

India’s weight-loss drug story has moved well beyond a niche pharmaceutical category. GLP-1 medicines are now creating a rapidly expanding business around obesity and metabolic health, with Mounjaro and semaglutide at the centre of the competition. India’s GLP-1 segment reached...

Seqonis Intelligent Operations by eschbach has a new dedicated capability called Leader Standard Work capability, which empowers pharmaceutical organizations to bring leadership routine planning, execution, documentation and evaluation into a single digital workflow. What does this mean for pharmaceutical manufacturers...

Nasal delivery is attracting interest for both systemic therapies and drugs targeting the central nervous system (CNS). The nasal mucosa offers a route to systemic absorption that avoids first-pass metabolism, while delivery via the olfactory and trigeminal pathways is...

Obesity treatment is entering a more competitive phase. Ozempic and Mounjaro helped make GLP-1-based medicines mainstream, but the next wave is looking beyond simply producing weight loss. The opportunity is significant because obesity remains widespread. U.S. data show that 40.3%...

Over the past two decades, the global pharmaceutical industry’s geography has changed profoundly: India’s pharmaceutical sector has evolved from a low-cost manufacturing base into a globally competitive industry capable of supplying regulated markets. China remains structurally critical, above all...

Opinion by Darren Bromley-Davenport, Technical Manager at Orbia Fluor & Energy Materials The transition to low-global warming potential (GWP) pressurised metered-dose inhalers (pMDIs) is now well underway. In recent years, significant progress has been made in identifying alternative propellants capable of...

When DeciBio asked nine senior pharma executives what was holding back AI adoption in R&D, the answer wasn't algorithms or compute. Three of the top four barriers they named were data problems, and low-quality data was cited by every...